tirzepatide and vision Why Your Changes on GLP-1 Medications (And What It Means) | Dr. Dan | Obesity Expert Comparative ocular outcomes of tirzepatide

In their marketing, telehealth companies claim that compounded GLP-1s in small doses starting lower than FDA-approved doses from Novo Nordisk and Eli Lilly can reduce metabolic risk, lower inflammatory markers, and even lower the risk of cognitive decline

, , ,

GLP-1s are still relevant to the growth narrative: management disclosed $230M (39%) in Q1 2025 and $190M (35%) in Q2 2025

Similarly to GLP-1 and its analogues, GLP-1RAs can modulate food intake and hedonic eating by targeting neural substrates, particularly within the mesolimbic reward pathways (e.g., VTA and NAc), altering satiety and reward responses to salient substances often subjected to abuse (Eren-Yazicioglu et al ., Reference Eren-Yazicioglu, Yigit, Dogruoz and Yapici-Eser2021